AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CinCor Pharma

NEW YORK , Jan. 9, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of CinCor Pharma, Inc. ("CinCor" or the "Company") (NASDAQ: CINC), in connection with the proposed acquisition of the Company by AstraZeneca PLC (NASDAQ: AZN) via tender offer. Under the terms of the merger agreement, the Company's shareholders will receive $26.00 in cash for each share of CinCor common stock owned, plus a non-tradable contingent value right ("CVR") of $10.00.

SHAREHOLDER ALERT: Weiss Law Investigates CinCor Pharma, Inc.

CinCor Pharma (CINC) announced that it has entered into a definitive agreement with AstraZeneca (AZN) under which AstraZeneca has agreed to acquire CinCor. These are the details.

Why AstraZeneca Is Buying CinCor Pharma For $1.8 Billion (AZN) (CINC)

AstraZeneca said it has agreed to buy CinCor Pharma, maker of clinical-stage blood pressure drug baxdrostat, in a deal valued at $1.8 billion. The post AstraZeneca To Acquire Blood-Pressure Drugmaker In $1.8 Billion Deal appeared first on Investor's Business Daily.

AstraZeneca To Acquire Blood-Pressure Drugmaker In $1.8 Billion Deal

AstraZeneca PLC (LSE:AZN) has announced it will acquire US-based biopharmaceutical firm CinCor for approximately US$1.8bn in an effort to boost its treatments of cardiorenal diseases. As part of the deal, AstraZeneca will also acquire CinCor's cash and marketable securities, valued at US$522mln late September.

AstraZeneca to acquire CinCor for US$1.8bn

European drugmakers on Monday announced a trio of deals around a billion dollars each to buy U.S.-listed biopharmas at hefty premiums.

European drugmakers including AstraZeneca pony up for U.S.-listed biopharmas

AstraZeneca said the deal, expected to close in the first quarter of 2023, will bolster its cardiorenal pipeline

AstraZeneca to Buy CinCor Pharma in $1.8 Billion Deal

For an initial $1.3 billion, the Anglo-Swedish company will acquire CinCor Pharma, including rights to its baxdrostat cardiorenal drug, which has shown promise in clinical trials.

AstraZeneca to Buy U.S. Cardiorenal-Drug Maker

AstraZeneca PLC said Monday that it has agreed to buy CinCor Pharma, Inc., acquiring global rights to the latter's baxdrostat cardiorenal drug for an upfront transaction value of around $1.3 billion.

AstraZeneca will buy U.S.-based CinCor for cardiorenal asset

AstraZeneca said on Monday it will buy U.S.-based clinical-stage biopharmaceutical firm CinCor Pharma Inc in a deal valued at about $1.8 billion to strengthen its pipeline of heart and kidney drugs.

AstraZeneca to buy U.S.-based CinCor Pharma in $1.8 bln deal

The Food and Drug Administration late Friday said that AstraZeneca Plc's AZN, +1.42% COVID-19 drug Evusheld may not provide protection against developing the illness in people exposed to XBB.1.5, one of the newest COVID subvariants. That's because XBB.1.5 is similar to other subvariants not neutralized by Evusheld, the FDA said.

AstraZeneca's COVID drug Evusheld unlikely to neutralize newest variant, FDA says

The FDA's decision on AstraZeneca (AZN)/Sanofi's (SNY) regulatory filing, seeking approval for using their RSV antibody in all infants, is expected in third-quarter 2023.

FDA Accepts AstraZeneca (AZN), Sanofi's RSV Antibody BLA

Biogen

These two stocks might go in different directions in the future.

1 Stock Defying the Downturn to Buy, and 1 to Avoid

GlaxoSmithKline

The global pharma sector is expected to see clinical trial readouts that could potentially de-risk approximately US$74bn of peak sales in 2023, according to a research report from Credit Suisse, This is in comparison to US$102bn of readouts in 2022 and US$78bn in 2021, excluding COVID-19-related treatments. The report also found that a record proportion of the 2023 readouts, approximately 40%, will come from line extensions where a drug is already approved for use in a different disease setting.

GSK, AstraZeneca: Will the two UK drugs giants ride the US$74bn pharma wave or will they be left beached?

CHICAGO--( BUSINESS WIRE )--Tempus, a leader in artificial intelligence and precision medicine, today announced a prospective study (NCT05257551), in collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN), that aims to identify biomarkers of response in patients with small cell lung cancer (SCLC). The study, titled Sculptor, is co-sponsored by Tempus and AstraZeneca's Personalize SCLC Initiative and is currently open for enrollment.

Tempus Announces Prospective Study for Biomarker Discovery in Small Cell Lung Cancer

A phase III clinical trial of a lung cancer drug developed by AstraZeneca PLC (LSE:AZN) and Daiichi Sankyo is expected to show positive results, according to a leading investment bank. The treatment, called Dato-DXd, is being tested in patients with non-small cell lung cancer (NSCLC) and is aimed at improving progression-free survival (PFS).

AstraZeneca: Has the market factored in the full value of potential cancer blockbuster?

Ahead of Dato-DXd TL01 study data, expected to be published by AstraZeneca PLC (LSE:AZN) by the end of Q1 2023, analysts at JPMorgan see a high positive "which should unlock multi-blockbuster potential". The analysts said they see a positive readout from the Phase III study in second-line non-small cell lung cancer (NSCLC) patients, de-risking around $3bn in peak potential in second-line NSCLC.

AstraZeneca Dato-DXd TL01 study data expected to be a high positive "which should unlock multi-blockbuster potential" - analysts

Caterpillar

e.l.f. Beauty

As last year's bear market spills over into 2023, breakout index stocks like CAT, BOX, AZN and ELF stock show resilience. The post Which Stocks Show Thick Skin As Bears Sink Fangs Into New Year?

Which Stocks Show Thick Skin As Bears Sink Fangs Into New Year?

TOKYO & MUNICH--( BUSINESS WIRE )--Daiichi Sankyo (TSE: 4568) today announced that the European Medicines Agency (EMA) has validated the Type II Variation application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations and who have received a prior systemic therapy.

ENHERTU® Type II Variation Application Validated by EMA for the Treatment of HER2 Mutant Metastatic Non-Small Cell Lung Cancer

AbbVie

Abbott Labs

Alnylam Pharmaceuticals

Amgen

argenx

Baxter

Bayer AG

BeiGene

Bristol-Myers

United States Brent Oil Fund LP

BioNTech SE

CSL Ltd

Invesco DB Oil Fund

Daiichi Sankyo Co Ltd

Gilead Sciences

Genmab - ADR

Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X Shares

iShares U.S. Oil & Gas Exploration & Production ETF

Incyte

Johnson & Johnson

Eli Lilly

Merck

Moderna

Novo Nordisk

Novartis

VanEck Vectors Oil Services ETF

iPath Pure Beta Crude Oil ETN

Pfizer

Invesco Dynamic Oil & Gas Services ETF

Reckitt Benckiser Group PLC

Regeneron Pharmaceuticals

Roche Holding AG

Royalty Pharma

Seagen

Takeda Pharmaceutical

ProShares Ultra Bloomberg Crude Oil

United States Oil Fund LP

Vertex Pharmaceuticals

SPDR S&P Oil & Gas Exploration & Production ETF

Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business Daily.

100 Best Stocks Of 2022: Oil Stocks And Medicals Shine

The Japanese Ministry of Health approves AstraZeneca's (AZN) Imfinzi plus Imjudo for treating advanced liver cancer and lung cancer.

AstraZeneca's (AZN) Imfinzi+Imjudo Gets Japan Nod for 2 Cancers

Japan just approved three drugs against cancer and leukemia. AstraZeneca increased its 2022 guidance.

AstraZeneca: Our 2023 Growth Pick

Broadcom

Innovative Industrial Properties

NextEra Energy

Novavax

You don't need a mountain of money to grow your wealth on Wall Street.

Got $1,000? 5 Sensational Stocks to Buy to Start 2023 With a Bang

The European Commission approves AstraZeneca's (AZN) two key cancer drugs Lynparza and Imfinzi for expanded use.

AstraZeneca (AZN) Gets EU Nod to Expanded Use of 2 Cancer Drugs

The CHMP recommends approvals for expanded use of AstraZeneca's (AZN) Enhertu in breast cancer, Imfinzi plus Imjudo in lung and liver cancers and Forxiga in heart failure.

AstraZeneca (AZN) Gets EU Nod & CHMP Opinions for Some Drugs

AstraZeneca's new asthma rescue treatment could soon be approved in the United States for adults.

Could AstraZeneca's Asthma Drug Candidate Generate Billions?

News for AstraZeneca Stock (AZN)